-
Mashup Score: 1EP 173: Tackling genetic cardiomyopathy with Eric Adler of Lexeo Therapeutics and UCSD - 1 hour(s) ago
Summary: This week on The Genetics Podcast, Patrick is joined by Eric Adler, Chief Medical Officer and Head of Research at Lexeo Therapeutics and Professor o…
Source: www.youtube.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 43Hold for PV100 2024 - 4 month(s) ago
News for pharmacy pros
Source: www.pharmavoice.comCategories: General Medicine News, CardiologistsTweet-
Honored to be named to the 2024 Pharmavoice 100 for the work done on behalf of patients suffering from cardiomyopathy. https://t.co/W1cDdSroJh
-
-
Mashup Score: 52Natural history and clinical outcomes of patients with hypertrophic cardiomyopathy from thin filament mutations - 8 month(s) ago
ESC Heart Failure is the open access journal of the ESC Heart Failure Association, dedicated to the advancement of knowledge in the field of heart failure management.
Source: onlinelibrary.wiley.comCategories: General Medicine News, CardiologistsTweet-
Congrats to Tatiana Saul, Quan Bui Alessia Argirio and colleagues for getting our paper on Thin Filament Cardiomyopathies accross the finish line! #thepeoplesfilament @UCSDCardiology @QuanBuiMD @AlessiaArgiro @IacopoOlivotto https://t.co/qBIBdiRETx
-
-
Mashup Score: 31
UC San Diego Continuing Professional Development, Precision Cardiovascular Care Symposium: Transitioning Care from Phenotypes to Genotypes – NO CME, 5/3/2024 7:00:00 AM – 5/3/2024 7:00:00 PM, Precision Cardiovascular Care Symposium: Transitioning Care from Phenotypes to Genotypes 2024 Hybrid Meeting Cardiovascular medicine is approaching a pivotal turning point, in which therapies introduced are shifting from those based on phenotype to those that treat the root underlying mechanism (endotype) and, more recently, the genetic cause (genotype). Such changes promise more effective therapies that promise to cure diseases instead of simply slowing down their progress. For this promise to be fulfilled, it will require more than developing new therapeutics -fundamental changes will need to occur in clinical practice, including how we identify at-risk patients, predict their disease trajectory, and monitor the benefit and side effects of new therapeutics. Symposium objectives: Provide an Over
Source: ucsd.cloud-cme.comCategories: General Medicine News, CardiologistsTweet-
Hope you can join us in person or virtually at the 1st annual Precision Cardiovascular Symposia Next Friday. All star line up of scientists, clinicians and trialists! Details below: https://t.co/CfzrZhyCXY @UCSDCardiology
-
-
Mashup Score: 29
UC San Diego Continuing Professional Development, Precision Cardiovascular Care Symposium: Transitioning Care from Phenotypes to Genotypes – NO CME, 5/3/2024 7:00:00 AM – 5/3/2024 7:00:00 PM, Precision Cardiovascular Care Symposium: Transitioning Care from Phenotypes to Genotypes 2024 Hybrid Meeting Cardiovascular medicine is approaching a pivotal turning point, in which therapies introduced are shifting from those based on phenotype to those that treat the root underlying mechanism (endotype) and, more recently, the genetic cause (genotype). Such changes promise more effective therapies that promise to cure diseases instead of simply slowing down their progress. For this promise to be fulfilled, it will require more than developing new therapeutics -fundamental changes will need to occur in clinical practice, including how we identify at-risk patients, predict their disease trajectory, and monitor the benefit and side effects of new therapeutics. Symposium objectives: Provide an Over
Source: ucsd.cloud-cme.comCategories: General Medicine News, CardiologistsTweet-
Hope you can join us in person or virtually at the 1st annual Precision Cardiovascular Symposia Next Friday. All star line up of scientists, clinicians and trialists! Details below: https://t.co/CfzrZhyCXY @UCSDCardiology
-
-
Mashup Score: 18International Consensus on Differential Diagnosis and Management of Patients With Danon Disease: JACC State-of-the-Art Review - 1 year(s) ago
Danon disease is a rare X-linked autophagic vacuolar cardioskeletal myopathy associated with severe heart failure that can be accompanied with extraca…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
https://t.co/d6YOXqiPhs An International Consensus on Danon Disease spearheaded by Kim Hong. https://t.co/WRhYcYi1Mu
-
-
Mashup Score: 2Applications of Gene Therapy in Cardiomyopathies: - 1 year(s) ago
Abstract Gene therapy is defined by the introduction of new genes or the genetic modification of existing genes and/or their regulatory portions, via gene replacement and gene editing strategies, r…
Source: www.jacc.orgCategories: Cardiologists, Latest HeadlinesTweet-
Applications of Gene Therapy in Cardiomyopathies | JACC: Heart Failure - a concise review on this hot topic https://t.co/YPotfMD7a8 Great job @AlessiaArgiro and co @QuanBuiMD @AmmiratiEnrico @IacopoOlivotto and Kim Hong! @UCSDCardiology
-
-
Mashup Score: 0Clinicle - The Medical Semantic Guessing Game - 2 year(s) ago
Guess the hidden medical diagnosis. A new puzzle is available every day.
Source: www.cliniclegame.comCategories: Cardiologists, Latest HeadlinesTweet-
I solved the semantic medical guessing game, @ClinicleGame Puzzle #23, in 1 guesses! See if you can beat me! https://t.co/7ItHaZq1bY #ClinicleGame #MedTwitter #SciTwitter #Medicine #Puzzles Great job @PMylavarapuMD
-
-
Mashup Score: 6Emerging Frontier in Heart Transplantation: Donation After Circulatory Death - American College of Cardiology - 2 year(s) ago
Quick Takes Machine perfusion enabled the success of DCD heart transplant by mitigating previous deleterious effects of warm ischemia. DCD and DBD heart transplant have similar outcomes. Widespread adoption of DCD heart transplant can expand the donor pool, resulting in increased transplant volume and decreased waitlist times. Figure 1 Courtesy of Lee C, Tsai C, Adler E,…
Source: American College of CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
Quick primer on DCD cardiac transplant: https://t.co/RW7axJWyox
-
-
Mashup Score: 6Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics - 2 year(s) ago
All muscle contraction occurs due to the cyclical interaction between sarcomeric thin and thick filament proteins within the myocyte. The thin filament consists of the proteins actin, tropomyosin, Troponin C, Troponin I, and Troponin T. Mutations in these proteins can result in various forms of cardiomyopathy, including hypertrophic, restrictive, and dilated phenotypes and account for as many as…
Source: FrontiersCategories: Cardiologists, Latest HeadlinesTweet-
https://t.co/efJV2gS2Br Are patients with Thin filament cardiomyopathy a different endotype? Strong work from Lucas Keyt, Jason Duran, and co! @jct_ucb @QuanBuiMD @UCSDCardiology
-
I had a great time doing The Genetics Podcast with Patrick. Got to talk about the field of genetic cardiomyopathy, the state of cardiovascular disease and of course… pizza. @UCSDCardiology #lexeotherapeutics https://t.co/1xH8ABRsQ6